Nuvation Bio Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvation Bio Inc. (NUVB)
CIK: 0001811063
Period of Report: 2021-02-10

Reporting Person: Hattersley Gary (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-10	Stock Option (Right to Buy)	$4.60	A	398935	Acquired	2030-10-04	Class A Common Stock (398935)	Direct
2021-02-10	Stock Option (Right to Buy)	$1.74	A	398935	Acquired	2030-01-21	Class A Common Stock (398935)	Direct

Footnotes

F1: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer").

F2: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria.

F3: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock.

F4: Options vest as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years.